natgillin/translations-raw huggingface dataset:
The risk of hypokalaemia is greater in patients with cirrhosis of liver, in patients experiencing brisk diuresis, in patients who are receiving inadequate oral intake of electrolytes and in patients receiving concomitant therapy with corticosteroids or Adrenocorticotropic hormone (ACTH) (see section 4.5). 
Rizik od hipokalemije veći je kod bolesnika s cirozom jetre, kod bolesnika koji su imali snažnu diurezu, te onih koji dobivaju neadekvatan oralni unos elektrolita i kod bolesnika koji su na istodobnom liječenju kortikosteroidima ili adrenokortikotropnim hormonom (ACTH) (vidjeti dio 4.5).
Therefore, it is not expected to potentiate bradykininmediated adverse effects. 
Stoga se ne očekuje potenciranje nuspojava posredovanih bradikininom.
Adverse reactions of unknown frequency reported with the use of hydrochlorothiazide alone include: Infections and infestations 
Nuspojave nepoznate učestalosti prijavljene uz primjenu samog hidroklorotiazida uključuju: Infekcije i infestacije Nepoznato:
If you forget to take Kinzalkomb 
Ako ste zaboravili uzeti Kinzalkomb
Therefore the use of a combination of telmisartan and ramipril is not recommended in this population. 
Stoga se ovoj populaciji ne preporučuje primjena kombinacije telmisartana i ramiprila.
Angiotensin II receptor antagonists should not be initiated during pregnancy. 
Primjena antagonista receptora angiotenzina II ne smije se započinjati u trudnoći.
Cough and angioedema were less frequently reported in patients treated with telmisartan than in patients treated with ramipril, whereas hypotension was more frequently reported with telmisartan. 
Kašalj i angioedem su bili rjeđe prijavljivani kod bolesnika liječenih telmisartanom nego kod bolesnika liječenih ramiprilom dok je hipotenzija bila češće prijavljivana uz telmisartan.
Telmisartan showed a similar effect to ramipril in reducing the primary composite endpoint of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for congestive heart failure. 
Telmisartan je pokazao sličan učinak kao i ramipril u smanjenju primarnog kompozitnog ishoda od kardiovaskularne smrti, nefatalnog infarkata miokarda, nefatalnog moždanog udara, ili hospitalizacije zbog kongestivnog zatajenja srca.
Untreated acute angle-closure glaucoma can lead to permanent vision loss. 
Neliječeni akutni glaukom zatvorenog kuta može dovesti do trajnog gubitka vida.
Co-administration of lithium and Kinzalkomb is not recommended (see section 4.4). 
Istodobna primjena litija i Kinzalkomba se ne preporučuje (vidjeti dio 4.4).
Dosage adjustment of the antidiabetic medicinal products may be required (see section 4.4). 
Može biti potrebna prilagodba doze antidijabetičkih lijekova (vidjeti dio 4.4).
What Kinzalkomb looks like and contents of the pack 
Kako Kinzalkomb izgleda i sadržaj pakiranja
In preclinical studies, no effects of telmisartan and hydrochlorothiazide on male and female fertility were observed. 
U pretkliničkim ispitivanjima nisu primijećeni učinci telmisartana i hidroklorotiazida na mušku i žensku plodnost.
Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction, resulting in acute transient myopia and acute angle-closure glaucoma. 
Hidroklorotiazid je sulfonamid, koji može izazvati idiosinkratičnu reakciju koja rezultira prolaznom akutnom miopijom i akutnim glaukomom zatvorenog kuta.
Telmisartan is metabolised by conjugation to form a pharmacologically inactive acylglucuronide. 
Telmisartan se metabolizira konjugacijom kako bi se formirao farmakološki neaktivni acilglukuronid.
If hypotension occurs, the patient should be placed in a supine position, with salt and volume replacements given quickly. 
Ako dođe do pojave hipotenzije, bolesnik se mora staviti u ležeći položaj, a nadoknada soli i volumena mora biti trenutna.
Metformin should be used with precaution: risk of lactic acidosis induced by a possible functional renal failure linked to hydrochlorothiazide. 
Metformin se mora primjenjivati s oprezom: rizik od laktacidoze induciran mogućim zatajenjem funkcije bubrega povezan je s hidroklorotiazidom.
If calcium supplements or calcium sparing medicinal products (e.g. vitamin D therapy) must be prescribed, serum calcium levels should be monitored and calcium dosage adjusted accordingly. 
Ako se moraju propisati nadomjesci kalcija ili lijekovi koji štede kalcij (npr. terapija vitaminom D), mora se pratiti serumske vrijednosti kalcija te u skladu s time prilagođavati doziranje kalcija.
Hypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of allergy or bronchial asthma, but are more likely in patients with such a history. 
Reakcije preosjetljivosti na hidroklorotiazid mogu se pojaviti kod bolesnika s ili bez anamneze alergija ili bronhijalne astme, ali su izglednije kod bolesnika s takvom anamnezom.
Telmisartan displaces angiotensin II with very high affinity from its binding site at the AT1 receptor subtype, which is responsible for the known actions of angiotensin II. 
Telmisartan izmješta angiotenzin II s vrlo velikim afinitetom s njegova mjesta vezivanja na AT1 podtipu receptora, koji je odgovoran za poznata djelovanja angiotenzina II.
Thiazides have been shown to increase the urinary excretion of magnesium, which may result in hypomagnesaemia (see section 4.5). 
Pokazalo se da tiazidi povećavaju ekskreciju magnezija urinom što može rezultirati hipomagnezemijom (vidjeti dio 4.5).
The most commonly reported adverse reaction is dizziness. 
Najčešća prijavljena nuspojava je omaglica.
An 80 mg dose of telmisartan administered to healthy volunteers almost completely inhibits the angiotensin II evoked blood pressure increase. 
Doza od 80 mg telmisartana primijenjena u zdravih pojedinaca gotovo u potpunosti inhibira povišenje krvnog tlaka uzrokovano angiotenzinom II.
Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors. 
Reverzibilno povećanje serumskih koncentracija litija i toksičnosti zabilježeno je tijekom istodobne primjene litija s inhibitorima enzima koji pretvara angiotenzin.
Very rare side effects (may affect up to 1 in 10,000 people): Increased pH (disturbed acid-base balance) due to low blood chloride level. 
Vrlo rijetke nuspojave (mogu se javiti u do 1 na 10 000 osoba): Povišen pH (poremećena acidobazna ravnoteža) zbog niske razine klorida u krvi.
Telmisartan belongs to a group of medicines called angiotensin II receptor antagonists. 
- Telmisartan pripada skupini lijekova koji se nazivaju antagonisti receptora angiotenzina II.
Overdose with hydrochlorothiazide is associated with electrolyte depletion (hypokalaemia, hypochloraemia) and hypovolaemia resulting from excessive diuresis. 
Predoziranje hidroklorotiazidom je povezano s deplecijom elektrolita (hipokalemija, hipokloremija) i hipovolemijom koja je rezultat prekomjerne diureze.
In a follow-up trial with the 80 mg/25 mg combination, blood pressure was further decreased (resulting in an overall reduction of 11.5/9.9 mm Hg (SBP/DBP). 
U ispitivanju praćenja (org. follow-up) s kombinacijom 80 mg/25 mg, krvni tlak se nastavio snižavati (što je rezultiralo ukupnim smanjenjem od 11,5/9,9 mm Hg (SKT/DKT).
Latent diabetes mellitus may become manifest during thiazide therapy. 
Latentni dijabetes melitus može se manifestirati tijekom terapije tiazidima.
Risk factors for developing acute angleclosure glaucoma may include a history of sulfonamide or penicillin allergy. 
Rizični faktori za razvoj akutnog glaukoma zatvorenog kuta mogu uključivati anamnezu alergije na sulfonamide ili penicilin.
Hydrochlorothiazide: Following oral administration of Kinzalkomb peak concentrations of hydrochlorothiazide are reached in approximately 1.0 - 3.0 hours after dosing. 
Hidroklorotiazid: Nakon peroralne primjene Kinzalkomba, vršne koncentracije hidroklorotiazida postižu se za oko 1,0-3,0 sati nakon doziranja.
These medicinal products may potentiate the effect of hydrochlorothiazide on serum potassium (see section 4.4). 
Ovi lijekovi mogu potencirati učinak hidroklorotiazida na serumski kalij (vidjeti dio 4.4).
Sorbitol and Lactose Monohydrate 
Sorbitol i laktoza hidrat
Telmisartan is an orally effective and specific angiotensin II receptor subtype 1 (AT1) antagonist. 
Telmisartan je oralno učinkovit i specifičan antagonist receptora podtipa 1 angiotenzina II (AT1).
Adverse reactions known to occur with each component given singly but which have not been seen in clinical trials may occur during treatment with Kinzalkomb. 
Nuspojave za koje se zna da se pojavljuju sa svakom komponentom zasebno, ali nisu bile primijećene u kliničkim ispitivanjima mogu se pojaviti tijekom liječenja Kinzalkombom.
No additional preclinical studies have been performed with the Fixed Dose Combination product 80 mg/25 mg. 
Nisu izvedene pretkliničke studije s fiksnom kombinacijom 80 mg/25 mg.
Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins. 
Apsorpcija hidroklorotiazida narušava se prisustvom smola anionske izmjene.
There was no evidence for benefit on cardiovascular mortality (hazard ratio 1.03, 95 % CI 0.85 - 1.24). 
Nije bilo dokaza pozitivnih učinaka na kardiovaskularnu smrtnost (omjer rizika 1,03, 95 % CI 0,85 - 1,24).
The diuretic action of hydrochlorothiazide reduces plasma volume, increases plasma renin activity, increases aldosterone secretion, with consequent increases in urinary potassium and bicarbonate loss, and decreases in serum potassium. 
Diuretsko djelovanje hidroklorotiazida smanjuje volumen plazme, povećava aktivnost renina u plazmi, povećava sekreciju aldosterona s posljedičnim povećanjem gubitka kalija i bikarbonata urinom, te smanjenjem kalija u serumu.
Infants whose mothers have taken angiotensin II receptor antagonists should be closely observed for hypotension (see sections 4.3 and 4.4). 
Dojenčad čije su majke uzimale antagoniste receptora angiotenzina II moraju se pažljivo promatrati radi hipotenzije (vidjeti dijelove 4.3 i 4.4).
Serum electrolytes and creatinine should be monitored frequently. 
Serumski elektroliti i kreatinin moraju se učestalo pratiti.
Based on available data from epidemiological studies, cumulative dose-dependent association between HCTZ and NMSC has been observed (see also sections 4.4 and 5.1). 
Na temelju dostupnih podataka iz epidemioloških ispitivanja, između hidroklorotiazida i NMSC-a primijećena je povezanost ovisna o kumulativnoj dozi (vidjeti također dijelove 4.4 i 5.1).
Thiazide diuretics may increase serum calcium levels due to the decreased excretion. 
Tiazidski diuretici mogu povećati razinu serumskog kalcija zahvaljujući smanjenoj ekskreciji.
The hazard ratio for telmisartan vs. ramipril was 1.01 (97.5 % CI 0.931.10, p (non-inferiority) = 0.0019 at a margin of 1.13). 
Omjer rizika za telmisartan naspram ramiprila bio je 1,01 (97,5 % CI 0,93 - 1,10, p (za neinferiornost) = 0,0019 na margini od 1,13).
The most prominent manifestations of telmisartan overdose were hypotension and tachycardia; bradycardia, dizziness, vomiting, increase in serum creatinine, and acute renal failure have also been reported. 
Najizraženije manifestacije predoziranja telmisartanom su hipotenzija i tahikardija; također su prijavljeni bradikardija, omaglica, povraćanje, povišene razine serumskog kreatinina i akutno zatajenje bubrega.
Thiazides should be used with caution in patients with impaired hepatic function (see section 4.4). 
Tiazidi se moraju primjenjivati s oprezom kod bolesnika s oštećenom jetrenom funkcijom (vidjeti dio 4.4).
Anorexia, appetite decreased, electrolyte imbalance, hypercholesterolaemia, hyperglycaemia, hypovolaemia. 
Anoreksija, smanjeni apetit, neravnoteža elektrolita, hiperkolesterolemija, hiperglikemija, hipovolemija.
Gastric lesions could be prevented/ameliorated by oral saline supplementation and group housing of animals. 
Gastrične lezije mogu se spriječiti/ublažiti oralnim nadomjescima soli i grupnim smještanjem životinja.
** Cases of progressive scarring of lung tissue have been reported during intake of telmisartan. 
** Slučajevi progresivnog nastanka ožiljaka u tkivu pluća prijavljeni su tijekom unosa telmisartana.
In case of surgery or anaesthetics, you should tell your doctor that you are taking Kinzalkomb. 
Ako trebate na operaciju ili primati anestetik, morate biti sigurni da Vaš liječnik zna da uzimate Kinzalkomb.
The antihypertensive efficacy of telmisartan is comparable to that of agents representative of other classes of antihypertensive medicinal products (demonstrated in clinical trials comparing telmisartan to amlodipine, atenolol, enalapril, hydrochlorothiazide, and lisinopril). 
Antihipertenzivna djelotvornost telmisartana usporediva je s djelotvornošću drugih lijekova koji spadaju u druge skupine antihipertenzivnih lijekova (pokazano u kliničkim studijama koje uspoređuju telmisartan s amlodipinom, atenololom, enalaprilom, hidroklorotiazidom i lizinoprilom).
Thiazides may decrease urinary calcium excretion and cause an intermittent and slight elevation of serum calcium in the absence of known disorders of calcium metabolism. 
Tiazidi mogu smanjiti ekskreciju kalcija urinom te izazvati povremeno i blago povišenje serumskog kalcija bez prisustva poznatih poremećaja u metabolizmu kalcija.
Thiazides may reduce the renal excretion of cytotoxic medicinal products and potentiate their myelosuppressive effects. 
Tiazidi mogu reducirati renalnu ekskreciju citotoksičnih lijekova i potencirati njihove mijelosupresivne učinke.
The active substances are telmisartan and hydrochlorothiazide. 
Djelatne tvari su telmisartan i hidroklorotiazid.
Furthermore, orthostatic hypotension may be aggravated by alcohol, barbiturates, narcotics or antidepressants. 
Nadalje, ortostatska hipotenzija može se pogoršati alkoholom, barbituratima, narkoticima, ili antidepresivima.
In dogs renal tubular dilation and atrophy were observed. 
Kod pasa su primijećeni renalna tubularna dilatacija i atrofija.
Medicinal products used in the treatment for gout (e.g. probenecid, sulfinpyrazone and allopurinol) Dosage adjustment of uricosuric medications may be necessary as hydrochlorothiazide may raise the level of serum uric acid. 
Lijekovi koji se primjenjuju u liječenju gihta (npr. probenecid, sulfinpirazon i alopurinol) Može biti potrebna prilagodba doze urikozuričnih lijekova s obzirom da hidroklorotiazid može povisiti razinu mokraćne kiseline u serumu.
Concomitant administration of hydrochlorothiazide and telmisartan does not appear to affect the pharmacokinetics of either substance in healthy subjects. 
Ne smatra se da istodobna primjena hidroklorotiazida i telmisartana utječe na farmakokinetiku jednog od njih kod zdravih osoba.
Although clinically significant hyperkalaemia has not been documented with Kinzalkomb, risk factors for the development of hyperkalaemia include renal insufficiency and/or heart failure, and diabetes mellitus. 
Iako klinički značajna hiperkalemija nije zabilježena uz Kinzalkomb, rizični faktori za razvoj hiperkalemije uključuju renalnu insuficijenciju i/ili zatajenje srca, te dijabetes melitus.
If these medicinal products are to be prescribed with the hydrochlorothiazide-telmisartan combination, monitoring of potassium plasma levels is advised. 
Ako se moraju propisati ovi lijekovi uz kombinaciju hidroklorotiazid-telmisartan, savjetuje se praćenje vrijednosti kalija u plazmi.
• Severe renal impairment (creatinine clearance <30 ml/min). 
• Teško oštećenje funkcije bubrega (klirens kreatinina <30 ml/min).
Based on the experience with the use of other medicinal products that blunt the renin-angiotensin system, concomitant use of the above medicinal products may lead to increases in serum potassium and is, therefore, not recommended (see section 
Na osnovi iskustva s primjenom drugih lijekova koji oslabljuju sustav renin-angiotenzin, istodobna primjena gore spomenutih lijekova može dovesti do povećanja kalija u serumu, te se stoga ne preporučuje (vidjeti dio 4.4).
In addition, there was a significantly higher incidence of hyperkalaemia, renal failure, hypotension and syncope in the combination arm. 
Nadalje, došlo je do značajno veće incidencije hiperkalemije, zatajenja bubrega, hipotenzije i sinkope u skupini liječenoj kombinacijom.
Non-steroidal anti-inflammatory medicinal products NSAIDs (i.e. acetylsalicylic acid at anti-inflammatory dosage regimens, COX-2 inhibitors and nonselective NSAIDs) may reduce the diuretic, natriuretic and antihypertensive effects of thiazide diuretics and the antihypertensive effects of angiotensin II receptor antagonists. 
NSAIL-i (tj. acetilsalicilatna kiselina u protuupalnim režimima doziranja, COX-2 inhibitori i neselektivni NSAIL-i) mogu reducirati diuretski, natriuretski i antihipertenzivni učinak tiazidskih diuretika te antihipertenzivni učinak antagonista receptora angiotenzina II.
Kinzalkomb should be kept in the sealed blister due to the hygroscopic property of the tablets. 
Kinzalkomb je potrebno čuvati u zatvorenom blisteru zbog higroskopskih svojstava tableta.
The use of Kinzalkomb during breast feeding is not recommended. 
Primjena Kinzalkomba tijekom dojenja se ne preporučuje.
The use of Kinzalkomb in children and adolescents up to the age of 18 years is not recommended. 
Primjena Kinzalkomba kod djece i adolescenata ispod 18 godina starosti se ne preporučuje.
Kinzalkomb may be less effective in lowering the blood pressure in black patients. 
Kinzalkomb može biti manje učinkovit u snižavanju krvnog tlaka kod bolesnika crne rase.
You should store your medicine in the original package in order to protect the tablets from moisture. 
Čuvati u originalnom pakiranju radi zaštite tableta od vlage.
In patients whose vascular tone and renal function depend predominantly on the activity of the reninangiotensin-aldosterone system (e.g. patients with severe congestive heart failure or underlying renal disease, including renal artery stenosis), treatment with medicinal products that affect this system has been associated with acute hypotension, hyperazotaemia, oliguria, or rarely acute renal failure (see section 4.8). 
Kod bolesnika čiji vaskularni tonus i bubrežna funkcija ovise uglavnom o aktivnosti sustava reninangiotenzin-aldosteron (npr. bolesnici s teškim kongestivnim zatajenjem srca ili oni s postojećom bubrežnom bolesti, uključujući stenozu bubrežne arterije), liječenje ostalim lijekovima koji utječu na ovaj sustav povezano je s akutnom hipotenzijom, hiperazotemijom, oligurijom, ili rijetko akutnim zatajenjem bubrega (vidjeti dio 4.8).
Due to the hydrochlorothiazide component, markedly low blood pressure and low blood levels of potassium can also happen, which may result in nausea, sleepiness and muscle cramps and/or irregular heartbeat associated with the concomitant use of drugs such as digitalis or certain anti-arrhythmic treatments. 
Zbog hidroklorotiazida kao komponente, također može doći i do izrazitijeg niskog krvnog tlaka i niskih vrijednosti kalija u krvi, što može rezultirati mučninom, pospanošću i grčevima mišića, i/ili nepravilnim otkucajima srca povezanim s istodobnom primjenom lijekova kao što su digitalis ili određeni antiaritmici.
What Kinzalkomb contains 
Što Kinzalkomb sadrži
The observed increased occurrence rate of sepsis associated with the use of telmisartan may be either a chance finding or related to a mechanism not currently known. 
Primijećena povećana stopa pojavnosti sepse povezana s primjenom telmisartana može biti zbog ili slučajnog otkrića ili nekog mehanizma koji za sada nije poznat.
In the "Prevention Regimen For Effectively avoiding Second Strokes" (PRoFESS) trial in patients 50 years and older, who recently experienced stroke, an increased incidence of sepsis was noted for telmisartan compared with placebo, 0.70 % vs. 0.49 % [RR 1.43 (95 % confidence interval 1.002.06)]; the incidence of fatal sepsis cases was increased for patients taking telmisartan (0.33 %) vs. patients taking placebo (0.16 %) [RR 2.07 (95 % confidence interval 1.14 - 3.76)]. 
U ispitivanju „Prevention Regimen For Effectively avoiding Second Strokes” (PRoFESS), provedenom na bolesnicima od 50 i više godina starosti, koji su nedavno imali moždani udar, zabilježena je povećana incidencija sepse uz telmisartan u usporedbi s placebom, 0,70 % u odnosu na 0,49 % [RR 1,43 (95 % interval pouzdanosti 1,00 - 2,06)]; incidencija slučajeva fatalne sepse je povećana za bolesnike koji su uzimali telmisartan (0,33 %) u odnosu na bolesnike na placebu (0,16 %) [RR 2,07 (95 % interval pouzdanosti 1,14 - 3,76)].
If you are intolerant to some sugars, consult your doctor before taking Kinzalkomb. 
Ako ne podnosite neke šećere, posavjetujte se s liječnikom prije početka primjene Kinzalkomba.
Thiazides may increase the risk of adverse effects caused by amantadine. 
Tiazidi mogu povećati rizik od nuspojava koje uzrokuje amantadin.
The degree to which hydrochlorothiazide is removed by haemodialysis has not been established. 
Stupanj do kojeg se hidroklorotiazid uklanja hemodijalizom nije utvrđen.
Telmisartan: The pharmacokinetics of orally administered telmisartan are non-linear over doses from 20 - 160 mg with greater than proportional increases of plasma concentrations (Cmax and AUC) with increasing doses. 
Telmisartan: Farmakokinetika peroralno primijenjenog telmisartana nije linearna u dozama od 20-160 mg s više nego proporcionalnim povećanjem koncetracija u plazmi (Cmax i AUC) pri rastućim dozama.
Hepatic function abnormal / liver disorder 
Abnormalna jetrena funkcija / poremećaj jetre
Although hypokalaemia may develop with the use of thiazide diuretics, concurrent therapy with telmisartan may reduce diuretic-induced hypokalaemia. 
Iako se hipokalemija može razviti s primjenom tiazidskih diuretika, istodobna terapija telmisartanom može reducirati hipokalemiju izazvanu diureticima.
Cholestyramine and colestipol resins 
Kolestiramin i kolestipol smole
The elimination half-life is not changed in patients with hepatic impairment. 
Poluvrijeme eliminacije je nepromijenjeno kod bolesnika s oštećenjem funkcije jetre.
In addition, Kinzalkomb should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma. 
Nadalje, Kinzalkomb se mora primjenjivati se s oprezom kod bolesnika s oštećenom jetrenom funkcijom ili progresivnom bolesti jetre, s obzirom da manje promjene u ravnoteži tekućine i elektrolita mogu precipitirati hepatičku komu.
Kinzalkomb may increase the blood pressure lowering effect of other medicines used to treat high blood pressure or of medicines with blood pressure lowering potential (e.g. baclofen, amifostine). 
Kinzalkomb može pojačati učinak snižavanja krvnog tlaka drugih lijekova koji se primjenjuju u liječenju visokog krvnog tlaka ili lijekova s potencijalom snižavanja krvnog tlaka (npr. baklofenak, amifostin).
Based on available data from epidemiological studies, cumulative dose-dependent association between HCTZ and NMSC has been observed. 
Na temelju dostupnih podataka iz epidemioloških ispitivanja, između HCTZ-a i NMSC-a primijećena je povezanost ovisna o kumulativnoj dozi.
Remove your Kinzalkomb tablet from the blister only directly prior to intake. 
Izvadite Kinzalkomb tabletu iz blistera neposredno prije primjene.
Kinzalkomb is a combination of an angiotensin II receptor antagonist, telmisartan, and a thiazide diuretic, hydrochlorothiazide. 
Kinzalkomb je kombinacija antagonista receptora angiotenzina II, telmisartana i tiazidskog diuretika, hidroklorotiazida.
As with other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy. 
Kao i uz druge vazodilatatore, potreban je poseban oprez kod bolesnika koji pate od aortalne i mitralne stenoze, ili opstruktivne hipertrofične kardiomiopatije.
Telmisartan: Following oral administration peak concentrations of telmisartan are reached in 0.5 - 1.5 h after dosing. 
Telmisartan: nakon peroralne primjene vršne koncentracije telmisartana postižu se 0,5-1,5 h nakon doziranja.
Upper respiratory tract infection, urinary tract infection including cystitis 
Infekcije gornjeg dišnog sustava, infekcije mokraćnog sustava uključujući cistitis